Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: If only I'd held who wrote (78988)	6/10/1999 4:05:00 PM
From: CoffeePot	Respond to of 119973

NERX good news today with TONS of insider buying Today's news biz.yahoo.com Insider buying since January total over 1.2mm shares biz.yahoo.com

To: If only I'd held who wrote (78988)	6/10/1999 4:05:00 PM
From: Ron	Read Replies (2) \| Respond to of 119973

NERX moving on this news. Also significant cancer research advance: biz.yahoo.com NeoRx's Pretarget-Lymphoma Produces Tumor Regressions LOS ANGELES-June 10, 1999--Dr. Hazel Breitz, Virginia Mason Medical Center (Seattle, WA), reported at the Society of Nuclear Medicine meeting that NeoRx Corporation's (Nasdaq:NERX - news) Pretarget® technology permitted the safe administration of higher radiation doses to lymphoma patients than conventional radioimmunotherapy, and that patients receiving these doses experienced substantial tumor regressions including complete responses in some cases. The maximum tolerated dose has not yet been reached. The abstract describing this work received the highest grade in the category of Therapeutic Oncology at the meeting. ''Both dosimetry calculations and the patients' tolerance and responses provide proof-of-concept that Pretarget technology may provide substantial benefits to lymphoma patients, even some who have had extensive prior therapies such as bone marrow transplantation,'' said Dr. Breitz. The Pretarget technology employed involves first injecting a tumor-directed antibody carrying avreceptor to the tumor, followed by a clearing step to remove the receptor from circulation. The radiation is then injected on a small molecule carrier that rapidly targets the receptor on the tumor,vwith most of the remaining radiation being quickly excreted from the body. By contrast, conventional approaches attach the radiation to the antibody that circulates throughout the body for a sustained period, increasing the radiation exposure to normal organs such as bone marrow. Patients involved in this proof-of-concept study included both intermediate and low-grade lymphoma patients, most of whose tumors had grown again after extensive prior therapies. Three patients had received high dose therapy requiring bone marrow transplantation; other patients had bone marrow that was extensively involved with tumor. ''It is remarkable, but not surprising, that even these patients tolerated these high doses well, and it is particularly gratifying that one of the complete responses was achieved in a patient who had received a prior stem cell transplant,'' said Paul Abrams, M.D., J.D, NeoRx's Chief Executive Officer. ''That is what this work is all about. Although this study was conducted with a commercially-available lymphoma antibody, NeoRx has now constructed its own proprietary molecule designed to improve binding to lymphoma cells and that may result in reduced manufacturing lead times and costs.'' NeoRx Corporation is developing innovative products designed to provide improved, cost-effective treatments for patients with cancer and inflammatory diseases.